Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial (2020)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1007/s40265-020-01323-x
- Subjects: ANTICOAGULANTES; ESTUDOS PROSPECTIVOS; FIBRILAÇÃO ATRIAL; QUIMIOTERAPIA COMBINADA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
NICOLAU, José Carlos et al. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, v. 80, n. 10, p. 995-1005, 2020Tradução . . Disponível em: https://doi.org/10.1007/s40265-020-01323-x. Acesso em: 21 jan. 2026. -
APA
Nicolau, J. C., Bhatt, D. L., Hohnloser, S. H., Kimura, T., Lip, G. Y. H., Miede, C., et al. (2020). Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, 80( 10), 995-1005. doi:10.1007/s40265-020-01323-x -
NLM
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2026 jan. 21 ] Available from: https://doi.org/10.1007/s40265-020-01323-x -
Vancouver
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2026 jan. 21 ] Available from: https://doi.org/10.1007/s40265-020-01323-x - Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
- Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- I Diretriz da Sociedade Brasileira de Cardiologia sobre processos e competências para a formação em cardiologia no Brasil: resumo executivo
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
Informações sobre o DOI: 10.1007/s40265-020-01323-x (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
